View clinical trials related to Cisplatin.
Filter by:Anlotinib is a novel oral multitarget tyrosine kinase inhibitor and primary targeted to VEGFR, FGFR, PDGFR and c-Kit. This study intends to assess the efficacy and safety of anlotinib combined with platinum/gemcitabine for first line treatment of advanced urothelial carcinoma.
In this study we will aim to determine if cisplatin ototoxicity can be prevented by intratympanic administration of corticosteroids.